Veteran finance and corporate strategist focused on growth-stage technology and healthcare investments, combining operating experience with board-level governance and capital-raising expertise. Krista D. McBeath brings experience in strategic M&A advisory, portfolio company scaling, and investor relations, with a track record of working across private equity, venture and corporate development teams to drive value creation and exit outcomes.
Veteran finance and corporate strategist focused on growth-stage technology and healthcare investments, combining operating experience with board-level governance and capital-raising expertise. Krista D. McBeath brings experience in strategic M&A advisory, portfolio company scaling, and investor relations, with a track record of working across private equity, venture and corporate development teams to drive value creation and exit outcomes.
Combines an operator-led, growth-stage investment approach emphasizing scalable technology and healthcare businesses. Prioritizes capital-efficient models, repeatable go-to-market strategies, and governance-ready leadership teams; favors active board engagement, staged capital deployment tied to operational milestones, and disciplined exit planning. Underwrites opportunities with an integrated M&A and capital markets lens, blending venture-like upside with private equity value-creation levers—product-market fit, commercial scaling, and strategic partnerships. Time horizon targets growth-to-exit (3–7 years) with emphasis on risk-managed concentration and measurable KPIs to drive dilution-aware returns.
Combines an operator-led, growth-stage investment approach emphasizing scalable technology and healthcare businesses. Prioritizes capital-efficient models, repeatable go-to-market strategies, and governance-ready leadership teams; favors active board engagement, staged capital deployment tied to operational milestones, and disciplined exit planning. Underwrites opportunities with an integrated M&A and capital markets lens, blending venture-like upside with private equity value-creation levers—product-market fit, commercial scaling, and strategic partnerships. Time horizon targets growth-to-exit (3–7 years) with emphasis on risk-managed concentration and measurable KPIs to drive dilution-aware returns.
| Trades 348 | Longs Won 261/348 75% | Profit Factor 30.07 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $734,755.15 |
| Average Win $240,343.03 | Best Trade (Aug 10) $9.44M | Sharpe Ratio 0.46 |
| Average Loss -$23,977.75 | Worst Trade (Mar 31) -$455,082.71 | Z-Score 3.3 (99.9%) |
| Commissions $0 | Avg. Trade Length 1y 3d | Expectancy $174,262.84 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 12,821 | 11,538 | 10,256 | 8,974 | 7,692 | 6,410 | 5,128 | 3,846 | 2,564 | 1,282 |